Innovative Biomarkers for Alzheimer's Disease

Focus on the Hidden Disease Biomarkers

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

The criteria for the clinical diagnosis of AD include the analysis of biomarkers of the underlying brain disease pathology; a set of cerebrospinal fluid (CSF) tests, amyloid-β1-42 (Aβ42), total-tau (t-tau), and phosphorylated tau (p-tau), are available and their performance in a clinical setting has been assessed in several studies. Thus, in dementia research, great advances have been made in the discovery of putative biomarkers; however, disappointingly, few of them have been translated into clinically applicable assays. To find biomarkers able to reliably detect AD pathology already at prodromal stages and in blood is even more important. Recent technical breakthroughs have provided ultrasensitive methods that allow the detection of brain-specific proteins in blood. In the present review, we will focus on the usefulness of ultrasensitive technologies for biomarker discovery and trace elements detection; moreover, we will review studies on circulating nano-compartments, a promising novel source of material for molecular diagnostics.

Original languageEnglish
Pages (from-to)1507-1518
Number of pages12
JournalJournal of Alzheimer's Disease
Volume62
Issue number4
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Alzheimer Disease
Biomarkers
Pathology
Prodromal Symptoms
Molecular Pathology
Trace Elements
Brain Diseases
Amyloid
Cerebrospinal Fluid
Dementia
Blood Proteins
Technology
Brain
Research

Keywords

  • Alzheimer's disease
  • biomarkers
  • extracellular vesicles/exosomes
  • trace elements

ASJC Scopus subject areas

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Innovative Biomarkers for Alzheimer's Disease : Focus on the Hidden Disease Biomarkers. / Ghidoni, Roberta; Squitti, Rosanna; Siotto, Mariacristina; Benussi, Luisa.

In: Journal of Alzheimer's Disease, Vol. 62, No. 4, 01.01.2018, p. 1507-1518.

Research output: Contribution to journalReview article

@article{95c0a207e48740678961b1b047f95959,
title = "Innovative Biomarkers for Alzheimer's Disease: Focus on the Hidden Disease Biomarkers",
abstract = "The criteria for the clinical diagnosis of AD include the analysis of biomarkers of the underlying brain disease pathology; a set of cerebrospinal fluid (CSF) tests, amyloid-β1-42 (Aβ42), total-tau (t-tau), and phosphorylated tau (p-tau), are available and their performance in a clinical setting has been assessed in several studies. Thus, in dementia research, great advances have been made in the discovery of putative biomarkers; however, disappointingly, few of them have been translated into clinically applicable assays. To find biomarkers able to reliably detect AD pathology already at prodromal stages and in blood is even more important. Recent technical breakthroughs have provided ultrasensitive methods that allow the detection of brain-specific proteins in blood. In the present review, we will focus on the usefulness of ultrasensitive technologies for biomarker discovery and trace elements detection; moreover, we will review studies on circulating nano-compartments, a promising novel source of material for molecular diagnostics.",
keywords = "Alzheimer's disease, biomarkers, extracellular vesicles/exosomes, trace elements",
author = "Roberta Ghidoni and Rosanna Squitti and Mariacristina Siotto and Luisa Benussi",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/JAD-170953",
language = "English",
volume = "62",
pages = "1507--1518",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - Innovative Biomarkers for Alzheimer's Disease

T2 - Focus on the Hidden Disease Biomarkers

AU - Ghidoni, Roberta

AU - Squitti, Rosanna

AU - Siotto, Mariacristina

AU - Benussi, Luisa

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The criteria for the clinical diagnosis of AD include the analysis of biomarkers of the underlying brain disease pathology; a set of cerebrospinal fluid (CSF) tests, amyloid-β1-42 (Aβ42), total-tau (t-tau), and phosphorylated tau (p-tau), are available and their performance in a clinical setting has been assessed in several studies. Thus, in dementia research, great advances have been made in the discovery of putative biomarkers; however, disappointingly, few of them have been translated into clinically applicable assays. To find biomarkers able to reliably detect AD pathology already at prodromal stages and in blood is even more important. Recent technical breakthroughs have provided ultrasensitive methods that allow the detection of brain-specific proteins in blood. In the present review, we will focus on the usefulness of ultrasensitive technologies for biomarker discovery and trace elements detection; moreover, we will review studies on circulating nano-compartments, a promising novel source of material for molecular diagnostics.

AB - The criteria for the clinical diagnosis of AD include the analysis of biomarkers of the underlying brain disease pathology; a set of cerebrospinal fluid (CSF) tests, amyloid-β1-42 (Aβ42), total-tau (t-tau), and phosphorylated tau (p-tau), are available and their performance in a clinical setting has been assessed in several studies. Thus, in dementia research, great advances have been made in the discovery of putative biomarkers; however, disappointingly, few of them have been translated into clinically applicable assays. To find biomarkers able to reliably detect AD pathology already at prodromal stages and in blood is even more important. Recent technical breakthroughs have provided ultrasensitive methods that allow the detection of brain-specific proteins in blood. In the present review, we will focus on the usefulness of ultrasensitive technologies for biomarker discovery and trace elements detection; moreover, we will review studies on circulating nano-compartments, a promising novel source of material for molecular diagnostics.

KW - Alzheimer's disease

KW - biomarkers

KW - extracellular vesicles/exosomes

KW - trace elements

UR - http://www.scopus.com/inward/record.url?scp=85044826021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044826021&partnerID=8YFLogxK

U2 - 10.3233/JAD-170953

DO - 10.3233/JAD-170953

M3 - Review article

VL - 62

SP - 1507

EP - 1518

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -